KaydedilenlerDerginizi ekleyin

Dergiler / Türkderm-Deri Hastalıkları ve Frengi Arşivi / 2019 / Cilt: 53 - Sayı: 1

Ustekinumab associated bullous pemphigoid in a psoriasis patient and a review of the literature

Aylin Okçu HEPER
Hatice ŞANLI
Seçil VURAL
Aylin Okçu HEPER
Nihal KUNDAKÇI
Pınar KORKMAZ
Mustafa GÜNDOĞDU
Pelin ERTOP
Sayfa
32–35
Yayın Tarihi
2022-11-06
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The resolution of BP after discontinuation of ustekinumab favors the diagnosis of drug-induced BP.Keywords: Psoriasis, ustekinumab, adverse effect, bullous pemphigoid

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Ustekinumab is a Food and Drug Administration-approved (2009) novel treatment for psoriasis patients.
📊
Temel Bulgular & Veri:This anti-interleukin-12/23p40 monoclonal antibody is effective in the treatment of plaque psoriasis and psoriatic arthritis.
💡
Sonuç & Katkı:The resolution of BP after discontinuation of ustekinumab favors the diagnosis of drug-induced BP.Keywords: Psoriasis, ustekinumab, adverse effect, bullous pemphigoid
🔬Tür:Araştırma Makalesi
📍Kapsam:2009 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Ustekinumab is a Food and Drug Administration-approved (2009) novel treatment for psoriasis patients. This anti-interleukin-12/23p40 monoclonal antibody is effective in the treatment of plaque psoriasis and psoriatic arthritis. Several drugs, including anti-tumor necrosis factor-alpha agents, used for psoriasis have been reported to induce or cause bullous pemphigoid (BP). A psoriasis patient presented with bullous lesions appearing on the extremities, groin, and axillary region four weeks after ustekinumab therapy. The patient was diagnosed with drug-induced BP. Ustekinumab was discontinued and the patient was treated with topical steroids and acitretin. The BP lesions did not recur in the twelve-month follow-up, after cessation of the steroids. Even though several drugs are related to the induction of BP, ustekinumab is included in this list recently. The resolution of BP after discontinuation of ustekinumab favors the diagnosis of drug-induced BP.Keywords: Psoriasis, ustekinumab, adverse effect, bullous pemphigoid

🔖

Bu Makaleye Atıf Yap

HEPER, A. O., ŞANLI, H., VURAL, S., HEPER, A. O., KUNDAKÇI, N., KORKMAZ, P., GÜNDOĞDU, M., ERTOP, P. (2022). Ustekinumab associated bullous pemphigoid in a psoriasis patient and a review of the literature. Türkderm-Deri Hastalıkları ve Frengi Arşivi, Cilt: 53 - Sayı: 1, 32–35. https://ajindex.com/articles/621681

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (18)

  1. Bolognia JL, Jorizzo JL, Rapini RP. Dermatology. Vol 1. 2 ed2008
  2. Prinz JC. Autoimmune aspects of psoriasis: Heritability and autoantigens. Autoimmun Rev 2017;16:970-9
  3. Wilczek A, Sticherling M. Concomitant psoriasis and bullous pemphigoid: coincidence or pathogenic relationship? Int J Dermatol 2006;45:1353-7
  4. Vassileva S. Drug-induced pemphigoid: bullous and cicatricial. Clin Dermatol 1998;16:379-87
  5. Duong TA, Buffard V, Andre C, et al. Efalizumab-induced bullous pemphigoid. J Am Acad Dermatol 2010;62:161-2
  6. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45
  7. Murayama H, Sakuma M, Takahashi Y, et al. Improving the assessment of adverse drug reactions using the Naranjo Algorithm in daily practice: The Japan Adverse Drug Events Study. Pharmacol Res Perspect 2018;6
  8. Newport MJ, Goetghebuer T, Marchant A. Hunting for immune response regulatory genes: vaccination studies in infant twins. Expert Rev Vaccines 2005;4:739-46
  9. Stavropoulos PG, Soura E, Antoniou C. Drug-induced pemphigoid: a review of the literature. J Eur Acad Dermatol Venereol 2014;28:1133-40
  10. Lee JJ, Downham TF 2nd. Furosemide-induced bullous pemphigoid: case report and review of literature. J Drugs Dermatol 2006;5:562-4
  11. Nakayama C, Fujita Y, Watanabe M, et al. Development of bullous pemphigoid during treatment of psoriatic onycho-pachydermo periostitis with ustekinumab. J Dermatol 2015;42:996-8
  12. Kobayashi TT, Elston DM, Libow LF, et al. A case of bullous pemphigoid limited to psoriatic plaques. Cutis 2002;70:283-7
  13. Stausbol-Gron B, Deleuran M, Sommer Hansen E, et al. Development of bullous pemphigoid during treatment of psoriasis with adalimumab. Clin Exp Dermatol 2009;34:285-6
  14. Wessman LL, Blixt EK, Wetter DA, et al. Adalimumab-associated bullous pemphigoid in a patient with ulcerative colitis. JAAD Case Rep 2017;3:339-41
  15. Wilmer EN, Becker N, Chen A, et al. Etanercept-induced generalization of chronic, localized, anogenital bullous pemphigoid in a psoriatic patient. JAAD Case Rep 2016;2:25-7
  16. Mochizuki M, Fujine E, Tawada C, et al. Pemphigoid nodularis possibly induced by etanercept. J Dermatol 2013;40:578-9
  17. Kluk J, Goulding JM, Bhat J, et al. Drug-induced bullous pemphigoid: cases triggered by intravenous iodine and etanercept. Clin Exp Dermatol 2011;36:871-3
  18. Bordignon M, Belloni-Fortina A, Pigozzi B, et al. Bullous pemphigoid during long